Safety of Controversial Vasculitis Drug Bolstered in Dedicated Trial

1 source1 article First seen 3 days ago Updated 3 days ago United States Truth score 38

Save Like Comments Compare coverage

Summary

(MedPage Today) -- ORLANDO -- Interim results from a prospective trial designed to evaluate safety of avacopan (Tavneos), the embattled drug for antineutrophil cytoplasmic antibody-associated vasculitis (AAV), indicated that the product could...

Description from Medpagetoday.

Who is covering this

Medpagetoday Center Factuality: Mostly factual US 3 days ago
Safety of Controversial Vasculitis Drug Bolstered in Dedicated Trial
(MedPage Today) -- ORLANDO -- Interim results from a prospective trial designed to evaluate safety of avacopan (Tavneos), the embattled drug for antineutrophil cytoplasmic antibody-associated vasculitis (AAV), indicated that the product could...

Comments

Comments need JavaScript.

Truth score

38/100Weakly supported

Independent outlets: 1
Source reliability: 65/100
Sides of the spectrum covering it: 1/3
Propaganda risk: 0/100

How well the story is corroborated by independent, reliable outlets across the spectrum. Not a fact-check of each claim. How the truth score works

Coverage by lean

Centre 100%100%

Left: 0
Centre: 1
Right: 0
Not rated: 0

How lean is counted

Source quality

Average reliability: 65/100 (Mostly factual)
Low-credibility outlets: 0%
State media: 0%
Opinion pieces: 0%

Where ratings come from

Where the coverage comes from

United States1

Filter the stories

Sources Ratings and details

Safety of Controversial Vasculitis Drug Bolstered in Dedicated Trial

Summary

Who is covering this

Comments